β2-adrenoceptors kick osteoarthritis – Time to rethink prevention and therapy

Although, during the past decades, substantial advances emerged in identifying major local and systemic factors contributing to initiation and progression of osteoarthritis (OA), some neuroendocrine mechanisms are still not understood or even neglected when thinking about novel therapeutic options....

Full description

Saved in:
Bibliographic Details
Published inOsteoarthritis and cartilage
Main Authors Jenei-Lanzl, Zsuzsa, Straub, Rainer H.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 28.06.2024
Subjects
Adrenergic therapy
Osteoarthritis
Sympathetic nervous system
β2-adrenoceptor
Sympathetic nervous system
Osteoarthritis
Adrenergic therapy
β2-adrenoceptor
Online AccessGet full text

Cover

More Information
Summary:Although, during the past decades, substantial advances emerged in identifying major local and systemic factors contributing to initiation and progression of osteoarthritis (OA), some neuroendocrine mechanisms are still not understood or even neglected when thinking about novel therapeutic options. One of which is the sympathetic nervous system that exhibits various OA-promoting effects in different tissues of the joint. Interestingly, the β2-adrenoceptor (AR) mediates the majority of these effects as demonstrated by several in vitro, in vivo as well as in clinical studies. This review article does not only summarize studies of the past two decades demonstrating that the β2-AR plays an OA-promoting role in different tissues of the joint but also aims to encourage the reader to think about next-level research to discover novel and innovative preventive and/or therapeutic strategies targeting the β2-AR in OA.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1063-4584
1522-9653
1522-9653
DOI:10.1016/j.joca.2024.06.012